Objective We evaluated adherence to and 1-year persistence of two third-generation anti-
seizure medications (ASMs), lacosamide and perampanel, in adult patients with focal …

Objective To compare medication adherence and healthcare utilization among patients who
were treated with anti-seizure medications (ASMs) as first add-on to monotherapy for …

Purpose Treatment for epilepsy primarily involves antiseizure medications (ASMs), which
can be characterized using the clinical data warehouse (CDW) database. In this study, we …

Purpose To estimate the rate of long-term lacosamide retention among a real-world group of
patients at a tertiary epilepsy center in Ireland. Methods One-hundred adults first prescribed …

Lacosamide (LCM) is a recently licensed antiepileptic drug available in the UK since 2008. It
is thought to act through modulation of sodium channel slow inactivation. Its efficacy and …

Objective This study aimed to assess the treatment compliance, patterns, healthcare
resource utilization (HCRU), and costs of anti-epilepsy drugs (AEDs) as the first add-on …

Objective Evidence for the efficacy and safety of adjunctive lacosamide in the treatment of
partial‐onset seizures (POS) was gained during placebo‐controlled clinical trials in patients …

Background and objectives Many patients with epilepsy are treated with antiepileptic drug
(AED) polytherapy. Several factors influence the choice of early add-on therapy, and …

Purpose To examine the rate of persistence with anti-seizure medications (ASMs) in a cohort
of patients with epilepsy, and to investigate the impact of a range of clinical and …

Purpose To evaluate the 1-year efficacy and safety of oral lacosamide as conversion
monotherapy in adult patients with partial onset seizures with or without generalization …